Gentle drug combo for AML or high-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two oral drugs (hydroxyurea and valproic acid, or 6-mercaptopurine and valproic acid) for people with AML or high-risk MDS who are too frail for standard chemotherapy. The goal is to see if this gentler treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is new, relapsed, or not responding to treatment
- You are not a candidate for standard strong chemotherapy, or you have chosen not to take it
- Your kidneys and liver are working well enough based on blood tests
- You are able to walk and do daily activities (even if you need some rest)
- You have not had any other cancer treatment in the last 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This trial adds a drug called hydroxyurea to a standard combination of chemotherapy for AML that has not responded to treatment or has come back. The hope is that adding hydroxyurea may make the other drugs work better.
This trial tests a combination of three drugs (hydroxychloroquine, decitabine, and venetoclax) for people with acute myeloid leukemia (AML) that is either hard to treat or very high-risk. The goal is to see if this combination can help control the leukemia and what side effects it may cause.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
Hear when a new Myelodysplastic Syndromes, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.